ぶどう膜新生物の世界市場レポート 2025年

ぶどう膜新生物市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR6.0％で14億5,000万米ドルに成長します。予測期間中の成長は、研究開発活動の増加、臨床試験数の増加、世界の疾患撲滅のための政府資金の増加、眼がんの罹患率の増加、ヘルスケア支出の増加に起因しています。主な動向としては、免疫療法の進歩、標的療法の開発、早期診断への重点化、臨床試験の増加、治療アプローチの革新などが挙げられます。

眼がんの罹患率の増加は、今後数年間のぶどう膜新生物市場の拡大を牽引すると予想されます。眼がんは、網膜、虹彩、視神経などさまざまな部位で発生する可能性のある眼球内の細胞の異常増殖を指します。このような眼がん患者の増加は、より良い検出方法、環境暴露、高齢化などの要因に起因すると考えられます。ぶどう膜新生物、特にぶどう膜黒色腫は、他の臓器、特に肝臓に転移する可能性があり、重大な健康リスクをもたらすまれなタイプの眼がんです。例えば、英国がん研究協会（Cancer Research UK）は、英国における眼がん罹患率は2023-2025年と2038-2040年の間に50％上昇し、2038年には人口10万人当たり年間平均3症例に達すると予測しています。この罹患率の上昇が、ぶどう膜新生物市場の成長に拍車をかけています。

ぶどう膜新生物市場の主なプレーヤーは、治療成績を改善し、患者により的を絞った選択肢を提供するために、T細胞受容体（TCR）治療薬などの革新的な治療法の開発に注力しています。T細胞受容体とは、T細胞の表面にあるタンパク質で、T細胞が特定の抗原を認識して結合し、免疫系が感染細胞やがん細胞を識別して攻撃することを可能にします。例えば、2022年1月、英国を拠点とするバイオテクノロジー企業Immunocore社は、切除不能または転移性のぶどう膜黒色腫の治療薬として承認された史上初のTCRベースの治療薬であるKIMMTRAK（tebentafusp-tebn）の米国FDA承認を取得しました。この画期的な治療法は、腫瘍細胞とT細胞の両方に結合し、免疫系ががんを認識して標的とするのを助ける。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界ぶどう膜新生物PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のぶどう膜新生物市場：成長率分析
• 世界のぶどう膜新生物市場の実績：規模と成長, 2019-2024
• 世界のぶどう膜新生物市場の予測：規模と成長, 2024-2029, 2034F
• 世界ぶどう膜新生物総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のぶどう膜新生物市場治療の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 薬物
• 治療
• 世界のぶどう膜新生物市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 注射剤
• その他のルート管理
• 世界のぶどう膜新生物市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• オンライン薬局
• 小売薬局
• 世界のぶどう膜新生物市場、薬物の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 化学療法剤
• 標的治療薬
• 免疫療法薬
• 世界のぶどう膜新生物市場、治療法のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 放射線治療
• レーザー療法
• 光線力学療法

第7章 地域別・国別分析

• 世界のぶどう膜新生物市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のぶどう膜新生物市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• ぶどう膜新生物市場：競合情勢
• ぶどう膜新生物市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • IDEAYA Biosciences Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• AstraZeneca plc
• Novartis AG
• Eli Lilly and Company
• Amgen Inc.
• Regeneron Pharmaceuticals Inc.
• Verastem Oncology Inc.
• Iovance Biotherapeutics Inc.
• Immunocore Holdings PLC
• Aura Biosciences
• Foghorn Therapeutics Inc.
• Syncona Limited
• iOnctura SA
• Linnaeus Therapeutics, Inc.
• Delcath Systems Inc
• Bellicum Pharmaceuticals Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• ぶどう膜新生物市場2029：新たな機会を提供する国
• ぶどう膜新生物市場2029：新たな機会を提供するセグメント
• ぶどう膜新生物市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Uveal neoplasms are tumors that develop in the uveal tract of the eye, comprising the iris, ciliary body, and choroid. These tumors can be benign (nevus) or malignant (uveal melanoma), impacting vision and potentially spreading to other parts of the body.

The main treatment options for uveal neoplasms are drugs and therapy. Uveal neoplasm drugs are medications used to treat tumors or cancerous growths in the uveal tract, targeting the iris, ciliary body, and choroid. These drugs are administered through various routes, including oral, injectable, and others, and are distributed through multiple channels, such as hospital pharmacies, online pharmacies, and retail pharmacies.

The uveal neoplasms market research report is one of a series of new reports from The Business Research Company that provides uveal neoplasms market statistics, including the uveal neoplasms industry global market size, regional shares, competitors with the uveal neoplasms market share, detailed uveal neoplasms market segments, market trends, and opportunities, and any further data you may need to thrive in the uveal neoplasms industry. This uveal neoplasms market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The uveal neoplasms market size has grown strongly in recent years. It will grow from $1.08 billion in 2024 to $1.15 billion in 2025 at a compound annual growth rate (CAGR) of 6.3%. The growth during the historic period can be attributed to the rising prevalence of uveal neoplasms, increased funding for personalized treatments, the growing elderly population, enhanced awareness and early detection, and the increase in cases of genetic disorders.

The uveal neoplasms market size is expected to see strong growth in the next few years. It will grow to $1.45 billion in 2029 at a compound annual growth rate (CAGR) of 6.0%. The growth during the forecast period can be attributed to increasing R&D activities, a growing number of clinical trials, rising government funding for global disease eradication, higher incidences of eye cancer, and increasing healthcare expenditures. Key trends include advancements in immunotherapy, the development of targeted therapies, a greater focus on early diagnosis, an increase in clinical trials, and innovations in therapeutic approaches.

The growing incidence of eye cancer is expected to drive the expansion of the uveal neoplasms market in the coming years. Eye cancer refers to the abnormal growth of cells in the eye, which can occur in various regions such as the retina, iris, or optic nerve. This increase in eye cancer cases may be attributed to factors such as better detection methods, environmental exposures, and an aging population. Uveal neoplasms, particularly uveal melanoma, are a rare type of eye cancer that can spread to other organs, especially the liver, posing significant health risks. For example, Cancer Research UK forecasts that eye cancer incidence rates in the UK will rise by 50% between 2023-2025 and 2038-2040, reaching an average of 3 cases per 100,000 people annually by 2038. This rising incidence is fueling the growth of the uveal neoplasms market.

Key players in the uveal neoplasms market are focusing on the development of innovative therapies, such as T cell receptor (TCR) therapeutics, to improve treatment outcomes and offer more targeted options for patients. T cell receptors are proteins on the surface of T cells that allow them to recognize and bind to specific antigens, enabling the immune system to identify and attack infected or cancerous cells. For example, in January 2022, Immunocore, a UK-based biotechnology company, received US FDA approval for KIMMTRAK (tebentafusp-tebn), the first-ever TCR-based therapy approved for treating unresectable or metastatic uveal melanoma. This groundbreaking therapy binds both to tumor cells and T cells, helping the immune system recognize and target the cancer.

In August 2023, TriSalus Life Sciences, a US-based oncology company, merged with MedTech Acquisition Corporation for an undisclosed amount. This merger aims to strengthen TriSalus' platform, improving treatments for liver and pancreatic cancers, including uveal melanoma with liver metastases. The move is expected to accelerate technology development, drive sales growth, and secure funding for key initiatives through mid-2024. MedTech Acquisition Corporation is a US-based special purpose acquisition company (SPAC) focused on merging with businesses in the medical technology sector.

Major players in the uveal neoplasms market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Merck & Co. Inc., IDEAYA Biosciences Inc., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, Eli Lilly and Company, Amgen Inc., Regeneron Pharmaceuticals Inc., Verastem Oncology Inc., Iovance Biotherapeutics Inc., Immunocore Holdings PLC, Aura Biosciences, Foghorn Therapeutics Inc., Syncona Limited, iOnctura SA, Linnaeus Therapeutics, Inc., Delcath Systems Inc, and Bellicum Pharmaceuticals Inc.

North America was the largest region in the uveal neoplasms market in 2024. The regions covered in uveal neoplasms report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the uveal neoplasms market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The uveal neoplasms market consists of revenues earned by entities by providing services such as diagnostic services, treatment services, and supportive services. The market value includes the value of related goods sold by the service provider or included within the service offering. The uveal neoplasms market also includes sales of diagnostic equipment, therapies, and pharmaceuticals. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Uveal Neoplasms Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on uveal neoplasms market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for uveal neoplasms ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The uveal neoplasms market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment Type: Drugs; Therapy
• 2) By Route Of Administration: Oral; Injectable; Other Route Administration
• 3) By Distribution Channel: Hospitals Pharmacies; Online Pharmacies; Retail Pharmacies
• Subsegments:
• 1) By Drugs: Chemotherapeutic Agents; Targeted Therapy Drugs; Immunotherapy Drugs
• 2) By Therapy: Radiation Therapy; Laser Therapy; Photodynamic Therapy
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd; Merck & Co. Inc.; IDEAYA Biosciences Inc.; Bristol-Myers Squibb Company
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Uveal Neoplasms Market Characteristics

3. Uveal Neoplasms Market Trends And Strategies

4. Uveal Neoplasms Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Uveal Neoplasms Growth Analysis And Strategic Analysis Framework

• 5.1. Global Uveal Neoplasms PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Uveal Neoplasms Market Growth Rate Analysis
• 5.4. Global Uveal Neoplasms Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Uveal Neoplasms Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Uveal Neoplasms Total Addressable Market (TAM)

6. Uveal Neoplasms Market Segmentation

• 6.1. Global Uveal Neoplasms Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Drugs
• Therapy
• 6.2. Global Uveal Neoplasms Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Injectable
• Other Route Administration
• 6.3. Global Uveal Neoplasms Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals Pharmacies
• Online Pharmacies
• Retail Pharmacies
• 6.4. Global Uveal Neoplasms Market, Sub-Segmentation Of Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chemotherapeutic Agents
• Targeted Therapy Drugs
• Immunotherapy Drugs
• 6.5. Global Uveal Neoplasms Market, Sub-Segmentation Of Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Radiation Therapy
• Laser Therapy
• Photodynamic Therapy

7. Uveal Neoplasms Market Regional And Country Analysis

• 7.1. Global Uveal Neoplasms Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Uveal Neoplasms Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Uveal Neoplasms Market

• 8.1. Asia-Pacific Uveal Neoplasms Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Uveal Neoplasms Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Uveal Neoplasms Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Uveal Neoplasms Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Uveal Neoplasms Market

• 9.1. China Uveal Neoplasms Market Overview
• 9.2. China Uveal Neoplasms Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Uveal Neoplasms Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Uveal Neoplasms Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Uveal Neoplasms Market

• 10.1. India Uveal Neoplasms Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Uveal Neoplasms Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Uveal Neoplasms Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Uveal Neoplasms Market

• 11.1. Japan Uveal Neoplasms Market Overview
• 11.2. Japan Uveal Neoplasms Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Uveal Neoplasms Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Uveal Neoplasms Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Uveal Neoplasms Market

• 12.1. Australia Uveal Neoplasms Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Uveal Neoplasms Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Uveal Neoplasms Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Uveal Neoplasms Market

• 13.1. Indonesia Uveal Neoplasms Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Uveal Neoplasms Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Uveal Neoplasms Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Uveal Neoplasms Market

• 14.1. South Korea Uveal Neoplasms Market Overview
• 14.2. South Korea Uveal Neoplasms Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Uveal Neoplasms Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Uveal Neoplasms Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Uveal Neoplasms Market

• 15.1. Western Europe Uveal Neoplasms Market Overview
• 15.2. Western Europe Uveal Neoplasms Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Uveal Neoplasms Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Uveal Neoplasms Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Uveal Neoplasms Market

• 16.1. UK Uveal Neoplasms Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Uveal Neoplasms Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Uveal Neoplasms Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Uveal Neoplasms Market

• 17.1. Germany Uveal Neoplasms Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Uveal Neoplasms Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Uveal Neoplasms Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Uveal Neoplasms Market

• 18.1. France Uveal Neoplasms Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Uveal Neoplasms Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Uveal Neoplasms Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Uveal Neoplasms Market

• 19.1. Italy Uveal Neoplasms Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Uveal Neoplasms Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Uveal Neoplasms Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Uveal Neoplasms Market

• 20.1. Spain Uveal Neoplasms Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Uveal Neoplasms Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Uveal Neoplasms Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Uveal Neoplasms Market

• 21.1. Eastern Europe Uveal Neoplasms Market Overview
• 21.2. Eastern Europe Uveal Neoplasms Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Uveal Neoplasms Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Uveal Neoplasms Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Uveal Neoplasms Market

• 22.1. Russia Uveal Neoplasms Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Uveal Neoplasms Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Uveal Neoplasms Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Uveal Neoplasms Market

• 23.1. North America Uveal Neoplasms Market Overview
• 23.2. North America Uveal Neoplasms Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Uveal Neoplasms Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Uveal Neoplasms Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Uveal Neoplasms Market

• 24.1. USA Uveal Neoplasms Market Overview
• 24.2. USA Uveal Neoplasms Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Uveal Neoplasms Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Uveal Neoplasms Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Uveal Neoplasms Market

• 25.1. Canada Uveal Neoplasms Market Overview
• 25.2. Canada Uveal Neoplasms Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Uveal Neoplasms Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Uveal Neoplasms Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Uveal Neoplasms Market

• 26.1. South America Uveal Neoplasms Market Overview
• 26.2. South America Uveal Neoplasms Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Uveal Neoplasms Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Uveal Neoplasms Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Uveal Neoplasms Market

• 27.1. Brazil Uveal Neoplasms Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Uveal Neoplasms Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Uveal Neoplasms Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Uveal Neoplasms Market

• 28.1. Middle East Uveal Neoplasms Market Overview
• 28.2. Middle East Uveal Neoplasms Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Uveal Neoplasms Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Uveal Neoplasms Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Uveal Neoplasms Market

• 29.1. Africa Uveal Neoplasms Market Overview
• 29.2. Africa Uveal Neoplasms Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Uveal Neoplasms Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Uveal Neoplasms Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Uveal Neoplasms Market Competitive Landscape And Company Profiles

• 30.1. Uveal Neoplasms Market Competitive Landscape
• 30.2. Uveal Neoplasms Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. IDEAYA Biosciences Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

31. Uveal Neoplasms Market Other Major And Innovative Companies

• 31.1. AstraZeneca plc
• 31.2. Novartis AG
• 31.3. Eli Lilly and Company
• 31.4. Amgen Inc.
• 31.5. Regeneron Pharmaceuticals Inc.
• 31.6. Verastem Oncology Inc.
• 31.7. Iovance Biotherapeutics Inc.
• 31.8. Immunocore Holdings PLC
• 31.9. Aura Biosciences
• 31.10. Foghorn Therapeutics Inc.
• 31.11. Syncona Limited
• 31.12. iOnctura SA
• 31.13. Linnaeus Therapeutics, Inc.
• 31.14. Delcath Systems Inc
• 31.15. Bellicum Pharmaceuticals Inc.

32. Global Uveal Neoplasms Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Uveal Neoplasms Market

34. Recent Developments In The Uveal Neoplasms Market

35. Uveal Neoplasms Market High Potential Countries, Segments and Strategies

• 35.1 Uveal Neoplasms Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Uveal Neoplasms Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Uveal Neoplasms Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer